ReviewHead & neck2025
Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service.
Review in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia
Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
Who cites it
16 citing papers in PubMed.
- Article
- Immunological Microenvironment Diversity in Homogeneous and Non-Homogeneous Oral Leukoplakia.International journal of molecular sciences · 2026Article
- Article
- Epithelial thickness as a new predictor of recurrence in oral leukoplakia after photodynamic therapy: a retrospective cohort study.BMC oral health · 2026Article
- Evidence-based review and clinical practice recommendations for the diagnosis and management of common oral mucosal lesions.World journal of experimental medicine · 2026Review
- Efficacy of 5-ALA Photodynamic Therapy in Dysplastic Oral Leukoplakia: Systematic Review and Meta-Analysis.Pharmaceutics · 2026Review
- A Retrospective Observational Study on Oral Leukoplakia Patients Adhering to the Mediterranean Diet From Southern Italy.International dental journal · 2026Observational
- Immune suppression, HLA-risk and potential future immune based targets of oral leukoplakia progression.Frontiers in dental medicine · 2026Review
- Laser Therapy Versus Conventional Treatments in Oral Leukoplakia: A Systematic Review of Efficacy, Recurrence, and Postoperative Outcomes.International journal of dentistry · 2026Review
- Evaluating patients with oral leukoplakia in smokers versus non-smokers: A clinico-histopathological study.Bioinformation · 2026Article
- Heterogeneous mechanisms, risk stratification, and translational advances in the malignant transformation of oral potentially malignant disorders to oral squamous cell carcinoma.Frontiers in molecular biosciences · 2026Review
- Chemopreventive Potential of Artemisinin andInternational journal of molecular sciences · 2025Article
- Advances in Photothermal Therapy for Oral Cancer.International journal of molecular sciences · 2025Review
- Cell-mediated mucositis of the oral cavity: narrative review on etiology, clinico-pathological aspects and malignant transformation.Pathologica · 2025Review
- Development and Evaluation of an Automated Multimodal Mobile Detection of Oral Cancer Imaging System to Aid in Risk-Based Management of Oral Mucosal Lesions.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Photobiomodulation therapy.JADA foundational science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral potentially malignant disorders (OPMDs) occur in up to 4%-5% of the population, of which oral leukoplakia (OL) is the most common subtype. Predicting high-risk OL remains a challenge. Early diagnosis and effective treatment are thought to be of paramount importance to improve outcomes.
methodsWe searched PubMed and Clinicaltrials.gov data for updates in the clinical management of OL from 2015 to current.
resultsRecent publication of large cohorts of patients with OL aids in counseling patients regarding risk of malignant transformation. Management for OL includes surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention. Several new entities show promise regarding candidate biomarkers, chemoprevention agents, and diagnostic adjuncts, though all require further validation.
conclusionThis update serves to further inform clinical management of OL and provide impetus for future investigations.
trial registrationNCT00099021, NCT00951379, NCT05727761, NCT05727761.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.